Shots:

• Dogma to receive upfront along with global regulatory and commercial milestones. AstraZeneca to get the rights to an orally active drug inhibiting PCSK9- offering a patient-friendly alternative to current cholesterol-lowering therapies that are delivered via a needle
• The agreement allows the AstraZeneca to develop the first small molecule- orally bioavailable PCSK9 inhibitor for patients at risk of cardiovascular disease
• PCSK9 is considered the exemplary target accredited by human genetics- as variants found in humans establish the needed directionality of a therapeutic

­ Ref: PRNewswire | Image: Business Standard